Immunic's MSToronto2026 Posters Reinforce Vidofludimus Calcium Signals but Remain Post-Hoc and Non-Confirmatory

What happened

Immunic presented four posters at MSToronto2026 featuring new data for vidofludimus calcium. Key highlights include CALLIPER open-label extension data suggesting durability of disability outcomes with continued treatment, preclinical evidence of Nurr1-dependent neuroprotection beyond DHODH inhibition, significant reductions in EBV-specific T-cell receptor signatures associated with improved cognition, and a novel disability measure suggesting overall benefit in progressive MS. However, these findings are largely exploratory or post-hoc, and the original CALLIPER primary endpoint miss on brain atrophy remains unaddressed. The safety and tolerability profile appears consistent with prior observations, with no new adverse signals reported. The data add mechanistic support but do not provide confirmatory evidence ahead of the pivotal ENSURE trials.

Implication

The new data reinforce vidofludimus calcium's potential beyond relapse suppression, but they are exploratory and post-hoc, so they carry limited weight in changing the risk-reward. The OLE durability supports disability outcome trends, but the primary endpoint miss still stands, so the neuroprotection claim remains unproven. The EBV TCR signature correlation with cognition is intriguing but needs prospective validation. Investors should focus on ENSURE Phase 3 results and cash runway; these posters may help attract partnership interest but do not eliminate the going-concern risk. Until definitive efficacy and financing clarity emerge, we maintain a neutral stance.

Thesis delta

The thesis shifts marginally positive due to additional supportive biomarker and preclinical data on neuroprotection and disability. However, the core investment case still hinges on ENSURE RMS outcomes and financing execution. The new data do not change the neutral/hold stance.